Variant LovD polypeptide
View Patent ↗The invention disclosed herein relates to methods and materials for producing simvastatin and related compounds such as huvastatin. In particular, the disclosure teaches that variants of the LovD acyltransferase polypeptide can be engineered to exhibit properties that facilitate their use in the production of simvastatin and/or huvastatin. The materials and processes disclosed herein are designed so that fermentation facilities currently producing lovastatin can be converted to producing simvastatin and related compounds with minimal modifications.
1. An isolated variant of a native LovD polypeptide, wherein the variant LovD polypeptide comprises at least two amino acid substitutions at an amino acid residue selected from the group consisting of: A10; D12; K26; A86; A190; H161; K227; G275; V334; and L361 of SEQ ID NO: 1, wherein the variant LovD polypeptide has an improved thermal stability as compared to the LovD polypeptide of SEQ ID NO:1.
2. The variant LovD polypeptide of claim 1 , wherein the variant LovD polypeptide further comprises amino substitutions at amino acid residue positions C40 and C60 of SEQ ID NO:1.
3. The variant LovD polypeptide of claim 1 , wherein the variant LovD polypeptide comprises amino acid substitutions selected from the group consisting of: A10V; D12G; K26E; C40A; C60N; A86V; H161Y; A190T; K227R; G275S; V334D; V334F; and L361M of SEQ ID NO:1.
4. The variant LovD polypeptide of claim 1 , wherein the at least two amino acid substitutions of the variant LovD polypeptide include at least one amino acid residue position selected from the group consisting of: K26, G275, and L361 of SEQ ID NO:1.
5. The variant LovD polypeptide of claim 1 , wherein the at least two amino acid substitutions of the variant LovD polypeptide include at least one amino acid residue selected from the group consisting of: K26E, G275S, and L361M of SEQ ID NO:1.
6. The variant LovD polypeptide of claim 2 , wherein the variant exhibits:
a decreased aggregation;
an improved catalytic activity;
an improved k cat /K m value;
an improved soluble expression level; or
an improved whole cell activity at 25° C.;
as compared to the LovD polypeptide shown in SEQ ID NO:1.
7. The variant LovD polypeptide of claim 1 , wherein the variant LovD polypeptide comprises amino acid substitutions at:
amino acid residue position A190;
amino acid residue positions D12, and G275;
amino acid residue positions D12, A190, and G275;
amino acid residue positions D12, K26, H161, A190, and G275;
amino acid residue positions A10, D12, K26, A190, and G275;
amino acid residue positions D12, K26, H161, A190, and G275;
amino acid residue positions D12, K26, H161, A190, G275, V334, and L361; or
amino acid residue positions D12, K26, H161, A190, G275, and V334 of SEQ ID NO:1.
8. The variant LovD polypeptide of claim 1 , wherein the variant LovD polypeptide comprises amino acid substitutions at:
D12G, C40A, C60N, A86V, A190T, and G275S;
D12G, K26E, C40A, C60N, A86V, H161Y, A190T, and G275S; or
D12G, K26E, C40A, C60N, A86V, H161Y, A190T, G275S, and V334F of SEQ ID NO:1.
9. A chimeric molecule comprising the variant LovD polypeptide of claim 1 , fused to a heterologous amino acid sequence.
10. An isolated variant of a native LovD polypeptide, wherein:
the variant LovD polypeptide comprises amino acid substitutions at an amino acid residue selected from the group consisting of: A10; D12; K26; A86; A190; H161; K227; G275; V334; and L361 of SEQ ID NO: 1, wherein the variant LovD polypeptide has an improved thermal stability as compared to the LovD polypeptide of SEQ ID NO:1; and
the variant LovD polypeptide is fused to a heterologous amino acid sequence.